The combination of pegylated human hyaluronidase (PEGH20) with gemcitabine and nab-paclitaxel (Abraxane) failed to improve the median overall survival (OS) in patients with metastatic pancreatic cancer, missing the primary endpoint of the phase III HALO-301 trial (NCT02715804), Halozyme Therapeutics, Inc. reported in a press release.
In addition to missing the primary endpoint, the combination arm also did not improve progression-free survival (PFS) or duration of response (DOR), 2 secondary endpoints of the trial. Read more . . .